Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Lyell Immunopharma, Inc. (LYEL)

Lyell Immunopharma Q2 net loss widens to $44.8 million; cash $228.0 million

Negative Impact 3 of 5 earnings Written later

Lyell Immunopharma reported a second-quarter 2026 net loss of $44.8 million, up from $42.7 million a year earlier, as research and development spending rose on increased clinical trial activity. The company had $228.0 million in cash, cash equivalents and marketable securities as of June 30, 2026, which it says is sufficient into the third quarter of 2027, and it reiterated that pivotal data from its PiNACLE trial are expected in mid-2027.

Key points

  • Net loss was $44.8 million for the quarter ended June 30, 2026, compared with $42.7 million in the same period of 2025.
  • R&D expenses rose to $39.5 million from $34.9 million, driven by an $8.8 million increase in research activities and outside services.
  • Cash, cash equivalents and marketable securities were $228.0 million as of June 30, 2026, down from $247.2 million at December 31, 2025.
  • Pivotal data from the PiNACLE trial of ronde-cel are expected in mid-2027, with a BLA submission expected to follow in the second half of 2027.

The filing

CompanyLyell Immunopharma, Inc. (LYEL)
Form8-K, current report
Filed with the SECAug 6, 2026, 4:14 PM ET
Accession number0001628280-26-054330

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 06, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.